Across TCGA pan-cancer cohorts, CPLX3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CPLX3 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CPLX3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CPLX3 expression acts as an unfavorable survival marker.

BLCA, STAD, and SARC are the cancer types where CPLX3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.083	0.572	<.001	18	view →
STAD	OS	Median	III,IV	0.003	0.633	<.001	12	view →
SARC	DFS	Median	All	0.095	0.632	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CPLX3 tumor-vs-normal RNA expression · all CPLX3 data types